Document:

Exhibit 10.11

 

AGREEMENT

 

AGREEMENT made and entered into as of the
1st day of May, 2015, (the “Agreement”) by and between 3D Total Solutions Inc., (the “Company”)
and Larry Dobroff (“CFO”).

 

WHEREAS, Company believes that it is in
the best interests of Company to utilize the experience and services of CFO pursuant to the terms herein; it is hereby

 

AGREED, that the Company hereby retains
the services of CFO under the following terms and conditions:

 

1. ENGAGEMENT. The Company agrees to engage CFO and
CFO agrees to serve as Chief Financial Officer of the Company, as set forth below.

 

2. TERM. The term of this Agreement shall be for a period
of one year commencing on May 1, 2015. Thereafter, this Agreement may be extended for periods by the mutual Agreement of the parties
hereto. Said extensions must be in writing, executed before the end of the initial term or any extension thereof.

 

3. SERVICE. In connection with the terms of this Agreement
the CFO shall perform those services normally associated with serving as Chief Financial Officer of a company reporting under the
Exchange Act of 1934, as amended

 

4. COMPENSATION. In exchange for the services rendered
hereunder by CFO, the Company hereby agrees to pay to CFO the following:

 

		•	$1,500 per month during the term of this Agreement.

		•	250,000 shares of the Company's Common Stock with standard restrictive legend on November 1, 2015
provided CFO is then the Chief Financial Officer of the Company (the “Shares”).

 

5. REPRESENTATIONS AND WARRANTIES OF THE Company.
The Company represents and warrants as follows:

 

A. The Company will cooperate fully and
in a timely manner with CFO to enable CFO to perform its obligations hereunder.

 

B. The execution and performance of this
Agreement by the Company has been duly authorized by the Board of Directors of the Company in accordance with applicable law and
the by-laws of Company.

 

C. The Company agrees that it will cooperate
with the CFO when/if CFO seeks to have the legend removed from the Shares pursuant to applicable regulations.

 

6. REPRESENTATIONS AND WARRANTIES OF THE CFO.
CFO hereby warrants and represents to the company as follows:

 

A. He has the authority to enter into this
Agreement and perform its obligations hereunder in the time and manner contemplated.

 

B. He has the requisite skill and experience
to perform the services and to carry out and fulfill his duties hereunder.

 

    	 

    	 

    

 

C. CFO’s investment in restricted
securities is reasonable in relation to the CFO’s net worth. CFO has had experience in investments in restricted and publicly
traded securities, and CFO has had experience in investments in speculative securities and other investments which involve the
risk of loss of investment. CFO acknowledges that an investment in the Shares is speculative and involves the risk of loss. CFO
has the requisite knowledge to assess the relative merits and risks of this investment without the necessity of relying upon other
advisors, and CFO can afford the risk of loss of his entire investment in the Shares.

 

D. CFO is acquiring
the Shares for the CFO’s own account for long-term investment and not with a view toward resale or distribution thereof except
in accordance with applicable securities laws.

 

7. NON-EXCLUSIVE SERVICES. The Company understands that
CFO and its agents are currently providing certain CFO services to other individuals or companies and CFO and its agents shall
not be prevented or estopped from rendering such services or services of the same or similar nature required under this Agreement,
to any other individual or entity. Furthermore, CFO understands and agrees that the Company shall be entitled to retain other persons
or entities to provide services of the same or similar nature to Company as those provided here-under by CFO.

 

8.Allocation
of Time and Energies. The CFO hereby promises to perform and discharge faithfully the responsibilities which may be assigned
to the CFO from time to time by the officers and duly authorized representatives of the Company in connection with the conduct
of its financial and public relations and communications activities, so long as such activities are in compliance with applicable
securities laws and regulations. CFO and staff shall diligently and thoroughly provide the consulting services required hereunder.
Although no specific hours-per-day requirement will be required, CFO and the Company agree that CFO will perform the duties set
forth herein above in a diligent and professional manner. The parties acknowledge and agree that a disproportionately large amount
of the effort to be expended and the costs to be incurred by the CFO and the benefits to be received by the Company are expected
to occur within or shortly after the first two months of the effectiveness of this Agreement. It is explicitly understood that
CFO's performance of its duties hereunder will in no way be measured by the price of the Company's common stock, nor the trading
volume of the Company's common stock.

 

9.NOTICES. All notices, requests,
and other communications hereunder shall be deemed to be duly given if sent by U.S. mail, postage prepaid, addressed to the other
party at the address as set forth herein below:

 

	To the Company:	3D Total Solutions Inc.
	 	75 Danbury Road

Ridgefield, CT 06877

	 	 
	To the CFO:	Larry Dobroff
	 	15 Southwick Court North

Plainview, NY 11803

	 	 

 

Either party may change
the address to which notices for it shall be addressed by providing notice of such change to the other party in the manner set
forth in this Section 10.

 

    	 

    	 

    

  

10. CONFIDENTIAL INFORMATION. Except
as permitted or directed by the Company’s Board of Directors in writing, or as required by operation of law, the CFO shall
be prohibited from divulging, furnishing or making accessible to anyone or use in any way (other than in the ordinary course of
business of the Company) any Confidential Information.  “Confidential Information” shall include the terms and
conditions of this Agreement, as well as any information of the Company or any affiliate, customer, subsidiary, supplier or other
business associate of the Company or any affiliate, including, but not limited to, any trade secrets or other private matters,
that the CFO has acquired or become acquainted with or will acquire or become acquainted during the term of this Agreement, whether
developed by the CFO or by others,  and which is not known or generally available to the general public or of a type
which the Company has customarily not made available to the general public, including but not limited to any trade secrets, confidential
or secret designs, processes, formulae, plans, devices or material (whether or not patented or patentable) directly or indirectly
useful or potentially useful to the Company, any customer or supplier lists of the Company, any confidential or secret development
or research work of the Company, or any other confidential or secret aspects of the business of the Company.   Both during
and after the term of this Agreement, the CFO shall refrain from any acts or omissions that would reduce the value of such knowledge
or information to the Company.  The foregoing obligations of confidentiality, however, shall not apply to any knowledge
or information that is published and publicly available, or which subsequently becomes generally publicly known in the form in
which it was obtained from the Company, other than as a direct or indirect result of the breach of this Agreement by the CFO.

 

11.SUCCESSORS AND ASSIGNS. This Agreement
shall inure to the benefit of and be binding upon the Company, its successors and assigns, including, without limitation, any corporation
which may acquire all or substantially all of the Company's assets and business or into which the Company may be consolidated or
merged.

 

12. Applicable
law. This Agreement shall be exclusively governed by, construed and enforced by the laws of the State of Connecticut without
giving effect to the principals of conflict of law. The parties agree that Fairfield County, Connecticut will be the exclusive
venue of any dispute and will have exclusive jurisdiction over all parties.

 

13. OTHER AGREEMENTS. This Agreement supersedes all
prior understandings and Agreements between the parties. It may not be amended orally, but only by a writing signed by parties.

 

14. HEADING. Headings in this Agreement
are for convenience only and shall not be used to interpret or construe its provisions.

 

15. COUNTERPARTS. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute
one and the instrument.

 

16.Waiver.
The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed
as a waiver of any subsequent breach by such other party.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement the day and year first above written.

 

“CFO”

 

By: _______________________

Larry Dobroff

 

 

“COMPANY”

3D TOTAL SOLUTIONS INC.

 

 

By: _______________________

James Endee, PresidentExhibit 10.1

 

JOINT DEVELOPMENT AGREEMENT

 

THIS JOINT DEVELOPMENT AGREMENT (this “Agreement”) is made as of November
1, 2013 (the “Effective Date”) by and between CDx, Inc., a Deleware corporation with its principal place of business
at 4225 Executive Square Suite 600, La Jolla, CA 92037 (“CDX”), and Next Dimension Technologies, Inc., a California corporation
with its principal place of business at 1 West Mountain Street, #11, Pasadena, CA 91103 (“NDT”). CDX and NDT are sometimes
referred to herein individually as the “Party” or collectively as the “Parties”.

 

WHEREAS, CDX would like to engage NDT to
develop chemical sensors and peripheral sensing equipment and software for the detection and characterization of cannabis and compounds
associated with cannabis; and

 

WHEREAS, NDT has accepted such responsibilities,
in accordance with the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the
mutual covenants contained herein and intending to be legally bound hereby, the Parties hereto agree as follows:

 

1.           Certain
Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 

“Detection Materials”
means chemical vapor detection systems, chemical sensors, or their associated hardware, software, or signal processing technology,
their progeny and unmodified derivatives, or related information and know-how.

 

“Field”  shall mean the
use of sensors and their associated hardware, software, or signal processing technology to characterize cannabis or to detect
or to quantify compounds in cannabis except for applications in law enforcement.

 

“Intellectual Property Rights”
means patents, applications for patents, utility models, applications for utility models, trademarks or trading names (whether
or not registered or registrable), domain names, rights in know-how (including trade secrets, technology, methods of manufacture,
specifications and other information relevant to the Field), designs (registered or umegistered and including applications for
registered designs), copyright (including rights in computer software), topography rights and other rights in semiconductor chips,
design rights, rights in inventions, the right to claim damages for past infringements of any or all such rights, the right to
claim priority for any or all such rights, and all rights having equivalent or similar effect wherever situated.

 

“Arising Intellectual Property Rights”
means such Intellectual Property Rights as are developed or created pursuant to this Agreement.

 

“Existing Intellectual Property Rights”
means any Intellectual Property Rights owned by or licensed to CDX or NDT prior to the Effective Date or created or resulting
after the Effective Date otherwise than under or pursuant to this Agreement.

 

    	1

    	 

    

 

2.           Services.

 

2.1           NDT Services.
NDT shall carry out consultancy, research, development, and/or other services to progress the work set forth in Exhibit A.
NDT will use reasonable efforts to satisfy its duties and provide the deliverables for each Task set forth in Exhibit A; provided,
however, that NDT does not represent or warrant that it will be able successfully to complete its assigned duties or deliverables.

 

2.2           Task
Authorization. NDT must not undertake any Task as defined in Exhibit A until CDX has provided written authorization to NDT
to do so. Notwithstanding the foregoing, NDT is authorized to undertake Task 1.1
as set forth in Exhibit A.

 

3.           Payments
and Expenses

 

3.1           Payments
for Services.  Inconsideration of NDT providing the services
hereunder as described in Exhibit A, CDX shall make non-refundable payments to NDT in accordance with the schedule of payments
associated with each Task as set forth in Exhibit A.

 

3.2           Invoice
Submission. NDT shall submit invoices to CDX for the full amount of each payment associated with each Task as set forth in
in Exhibit A. All invoices shall be payable ten (10) days after receipt by CDX.

 

4.           Intellectual
Property. The Parties agree to the applicable provisions as to ownership, use and/or exploitation oflntellectual Property Rights
as follows:

 

4.1           Disclosure.
Ifduring the Term of this Agreement either Party (or an authorized
sub-contractor of it) develops or creates (whether with or without others and whether jointly with the other Party or not) any
Arising Intellectual Property Rights, they shall forthwith disclose any such Arising Intellectual Property Rights to the other.

 

4.2           Arising
IP Belonging to NDT.
Any Arising Intellectual Property Rights outside of the Field shall belong to NDT, and any Arising Intellectual Property Rights
relating to improvements to Detection Materials shall belong to NDT. To the extent that CDX would otherwise be the owner in whole
or in part of any such rights, CDX shall promptly upon request from NDT assign its entire right, title and interest to any and
all such Arising Intellectual Property Rights to NDT for a nominal (less than $100.00) consideration.

 

4.3           Arising
IP Belonging to CDX.
Any Arising Intellectual Property Rights other than those covered by Paragraph 4.2 shall belong to CDX. To the extent that NDT
would otherwise be the owner in whole or in part of any such Arising Intellectual Property Rights, NDT shall promptly upon request
from CDX assign its entire right, title and interest to any and all such Arising Intellectual Property Rights to CDX for a nominal
(less than $100.00) consideration.

 

4.4           Arising
IP Rights Granted to CDX. To the extent that it is necessary to do so to enable CDX to use and exploit its respective Arising
Intellectual Property Rights, NDT hereby grants CDX a perpetual, irrevocable, exclusive, and royalty free license (including the
right to assign the license and to grant sub-licenses) to use and exploit NDT’s Arising Intellectual Property Rights in
the Field.

 

    	2

    	 

    

 

4.5           Notice
oflP Infringement. During the term of this Agreement and upon their knowledge of the occurrence of any infringement or suspected
or threatened infringement of any of the Arising Intellectual Property Rights or the Existing Intellectual Property Rights in the
Field, or any proceedings or suspected or threatened proceedings for the revocation or involving the validity of any of the Intellectual
Property Rights, the Party with this knowledge shall notify the other and provide all details within their knowledge with respect
to the same and thereafter the Parties will assist each other in taking such steps as either Party may reasonably consider to be
appropriate at the expense of the Party that considers such steps to be appropriate.

 

4.6           Reverse
Engineering. CDX shall not reverse engineer, copy, disassemble, modify, decompile, or make any other attempt to ascertain the
composition or the properties and characteristics of the prototypes, software, or other tangible objects which are provided or
developed pursuant to this Agreement by NDT. In the event any such actions nevertheless occur, all data and results and/or any
inventions, discoveries, or works arising there from shall be solely owned by NDT and CDX shall, at its expense, assign any such
inventions or discoveries to NDT.

 

4.7           Evaluation.
CDX shall not conduct any tests, evaluations or research outside of the Field using prototypes, software, or other tangible
objects which are provided pursuant to this Agreement to CDX by NDT. In the event any such actions nevertheless occur, all data
and results and/or any inventions, discoveries, or works arising there from shall be solely owned by NDT and CDX shall, at its
expense, assign any such inventions or discoveries to NDT.

 

4.8           Licensing
of Existing Intellectual Property Rights. The Parties agree to the applicable provisions as to the licensing, use and/or exploitation
of Existing Intellectual Property Rights as set forth in Exhibit B.

 

5.           Confidentiality.

 

5.1           Non-Disclosure.
The non-disclosure agreement between the parties in effect as of April 20, 2012 (the “Non-Disclosure Agreement”)
will apply throughout and survive the termination or expiration of this Agreement. “Confidential Information” shall have
the same meaning in this Agreement as it has in the Non-Disclosure Agreement.

 

5.2           Disclosers.
 “Discloser” shall mean either Party or any of its affiliates disclosing Confidential Information to the Recipient.

 

5.3           Recipients.
 “Recipient” shall mean either Party or any of its affiliates receiving Confidential Information from the Discloser.

 

5.4           Disclosure
of Confidential Information. Each Party will disclose to the other such Confidential Information as it considers necessary
to further the purpose of this Agreement. The terms of this Agreement shall be considered Confidential Information of both Parties.

 

5.5           Use
of Confidential Information. The Recipient shall only use Confidential Information to further the purpose of this Agreement
and for no other purpose.

 

5.6           Obligation
of Recipient. The Recipient shall not without the prior written consent of the Discloser communicate or otherwise make available
the Confidential Information to any third party save in so far as is necessary for an application for registration of an Arising
Intellectual Property Right. The Recipient shall forthwith notify the Discloser of any such application and the Discloser may refuse permission to allow publication. However,
such permission may not be reasonably refused.

 

    	3

    	 

    

 

5.7           Use
of Company Names and Logos. Neither Party will, without the prior written consent of the other Party: (a) use in advertising,
publicity, or otherwise in connection with products developed in accordance with this Agreement, any trade name, logo, trademark,
trade device, service mark, or symbol owned by the other Party; or (b) represent, either directly or indirectly, that any product
or service of the other Party is a product or service of the representing Party, or vice versa.

 

6.           Return
of Data and Samples

 

6.1           Except
as set forth in the Non-Disclosure Agreement, each Party shall return to the other upon demand any remaining samples, prototypes
and all copies of Confidential Information and will destroy all notes and any other written reports or documents which may have
been made by the Recipient to the extent they contain any part of or reference to the Confidential Information in whole or part
except as authorized in writing by the Discloser or if required by law.

 

7.           Warranties
and Indemnification

 

7.1           Warranties
to Both Parties. Each Party warrants to the other that:

 

(a)          it
has full right and authority to enter this Agreement, that it has had an opportunity to review this Agreement and that it understands
and agrees to each of the provisions herein; and

 

(b)          to
its knowledge, its execution and performance of this Agreement does not and will not cause it to be in breach of any obligation
whether contractual, statutory or otherwise.

 

7.2           Warranties
by NDT. NDT further warrants to CDX that:

 

(a)          it
possesses the necessary skill and expertise to perform the services under this Agreement and shall devote to the services under
this Agreement all of the reasonable time, attention and skill as may be necessary for the proper performance of the services set
forth in Exhibit A;

 

(b)          there
is no known litigation pending or threatened in relation to any of its Existing Intellectual Property Rights which are in or relevant
to the Field; and

 

(c)          in
carrying out its obligations under this Agreement, it shall not knowingly infringe the Intellectual Property Rights of any third
party

 

7.3           Disclaimer
of Warranty. DETECTION MATERIAL DELIVERED BY NDT TO CDX PURSUANT TO THIS AGREEMENT IS PROVIDED “AS IS.” EXCEPT AS
EXPRESSLY PROVIDED IN PARAGRAPHS 7.1 AND 7.2, NDT PROVIDES NO WARRANTIES FOR THE DETECTION MATERIAL, EXPRESS OR IMPLIED, EITHER
IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE, AND NDT SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY,
ANY IMPLIED WARRANTY
OF FITNESS FOR A PARTICULAR PURPOSE, AND ANY IMPLIED WARRANTY OF NON-INFRINGEMENT. ALL CHARACTERISTICS OF THE DETECTION MATERIAL
ARE NOT FULLY UNDERSTOOD AND ITS USE MAY INVOLVE RISKS OR DANGERS THAT ARE NOT KNOWN OR FULLY APPRECIATED. EXCEPT AS EXPRESSLY
PROVIDED IN PARAGRAPHS 7.1 AND 7.2, DETECTION MATERIAL DELIVERED BY NDT TO CDX PURSUANT TO THIS AGREEMENT IS BEING PROVIDED WITHOUT
WARRANTY OF ANY SORT, EXPRESS OR IMPLIED.

 

    	4

    	 

    

 

7.4           Indemnification
by CDX. CDX shall indemnify and hold harmless NDT, its officers, directors, employees, agents, and affiliates from any and
all third-party claims, including attorneys’ fees, related to: CDX’s negligent, reckless, or intentional action or inaction related
to this Agreement; or CDX’s breach of this Agreement.

 

7.5           Indemnification
by NDT. NDT shall indemnify and hold harmless CDX, its officers, directors, employees, agents, and affiliates from any and
all third-party claims, including attorneys fees, related to: NDT’s negligent, reckless, or intentional action or inaction related
to this Agreement; or NDT’s breach of this Agreement.

 

7.6           Conditions
of Indemnification. The indemnification obligations Paragraphs 7.4 and 7.5 are conditioned upon: (a) The indemnifying Party
is notified promptly in writing of any claim against the indemnified Party; (b) The indemnifying Party shall control any settlement,
defense or prosecution of the claim and is permitted to defend, compromise, or settle such claim, as long as such action does not
adversely impact the other Party; and (c) The indemnifying Party is given all available information, cooperation, assistance, and
authority as reasonably necessary to carry out its obligations.

 

7.7           No
Guarantee of Success. The Parties will use reasonable efforts to satisfy their respective duties and provide the deliverables
for each effective project; provided, however, that neither Party represents or warrants that it will be able successfully to complete
its assigned duties or deliverables.

 

8.           Assignment.

 

8.1           Assignment
of Agreement. Neither Party may assign or otherwise directly or indirectly transfer this Agreement or the rights and obligations
hereunder to any person or entity other than a wholly-owned subsidiary without the prior written consent of the other Party. Notwithstanding
the above:

 

(a)          CDX
may assign this Agreement, without consent, (a) in whole or in part, to an affiliate or subsidiary or (b) in the event of a change
of controlling ownership (either directly or indirectly) in CDX or in the event of merger, recapitalization, consolidation, other
business combination or sale of all or substantially all of the assets of CDX.

 

(b)          NDT
may assign this Agreement, without consent, (a) in whole or in part, to an affiliate or subsidiary or (b) in the event of a change
of controlling ownership (either directly or indirectly) in NDT or in the event of merger, recapitalization, consolidation, other
business combination or sale of all or substantially all of the assets of NDT.

 

    	5

    	 

    

 

9.           Term
and Termination.

 

9.1           Term. This
Agreement shall become effective on the Effective Date and shall expire two years following the Effective Date.

 

9.2           Termination
at End of Tasks. Either Party shall have the right to terminate this Agreement at its own discretion upon the completion of
all Tasks in Exhibit A that have been authorized in accordance with the terms of Paragraph 2.2. Notwithstanding this provision,
before or upon the successful completion of Phase 3, the parties will work to conclude a suitable Supply Agreement by which NDT
will supply CDX with sensors on a commercial basis. In the event that NDT is unable to supply the sensors, NDT agrees to negotiate
in good faith with CDX a worldwide license in the Field to any NDT Existing Intellectual Property Rights necessary to make, have
made, use, sell or offer for sale the sensors.

 

9.3           Termination
By Either Party. This Agreement may be terminated forthwith upon notice being given by either Party to the other if:

 

(a)          the
other goes into liquidation, commences bankruptcy proceedings, or if a receiver or administrative receiver or administrator is
appointed in respect of the whole or any part of its assets; or

 

(b)          the
other makes an assignment for the benefit of or composition with its creditors generally or threatens to do any of these things
or does or suffers any similar occurrence in any other jurisdiction; or

 

(c)          the
other commits a breach of any term of this Agreement which is incapable of remedy or, in the case of a breach capable of being
remedied, shall have failed within thirty (30) days after receipt of notice from the other Party so to do, to remedy such breach
to the reasonable satisfaction of the other Party.

 

9.4           Survival
of Termination. Termination (or expiration) of this Agreement shall be without prejudice to any assignment or license of intellectual
property granted under or pursuant to this Agreement and to any rights either Party may have accrued as at the date of such termination
(or expiration). In particular the provisions relating to intellectual property (Paragraph 4, inclusive), confidentiality (Paragraph
5, inclusive), and return of data and samples (Paragraph 6, inclusive) shall survive termination (or expiration) of this Agreement.

 

10.         General
Provisions. 

 

10.1         Notices.
All notices pursuant to this Agreement shall be deemed properly given:

 

(a)          When
personally delivered;

 

(b)          Upon
receipt of a facsimile or electronic message and confirmed by first-class mail, postage prepaid;

 

(c)          Upon
receipt by overnight delivery; or

 

(d)          When
sent by Certified or Registered mail, postage prepaid and properly addressed to the representatives named below at the appropriate
address first written above or at such other address as the parties may so notify in writing:

 

    	6

    	 

    

 

		CDX:	Attention:   Daniel Yazbeck

Title:   President

 

		NDT:	Attention:   William Royea

Title:   President

 

10.2         Entire
Agreement. This Agreement constitutes the entire agreement of the parties and supersedes any and all prior agreements or understanding
of the parties, either written or oral, regarding the subject of this Agreement.

 

10.3         Waiver.
This Agreement may be modified or amended only by the written agreement of the Parties hereto. A waiver by any Party of any
default or breach by another Party of any provision of this Agreement shall not be considered as a waiver of any subsequent default
or breach of that same provision or of any other provision hereof. The failure by any Party to object to or to take affirmative
action with respect to any conduct of another Party which is in violation of any provision of this Agreement shall not be construed
as a waiver thereof, nor of any future breach or subsequent wrongful conduct.

 

10.4         Severability.
Each provision of this Agreement is severable and distinct from the others and if any provision is or at any time becomes to
any extent or in any circumstances invalid, illegal or unenforceable for any reason, it shall to that extent or in those circumstances
be deemed not to form part of this Agreement, but the validity, legality and enforceability of all other provisions of this Agreement
shall not otherwise be affected or impaired, it being the Parties’ intention that every provision of this Agreement shall be and
remain valid and enforceable to the fullest extent permitted by law.

 

10.5         Headings.
The headings in this Agreement are inserted for convenience only and shall not constitute a part hereof.

 

10.6         Choice
of Law. The Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard
to its conflicts of laws provisions. In the event of any disputes both parties will use all reasonable endeavors to settle all
matters in dispute amicably. Any dispute which cannot be resolved amicably by the parties will be submitted to the exclusive jurisdiction
of the federal courts of the State of California and the parties agree to submit to the exclusive jurisdiction of the federal courts
of the State of California.

 

10.7         Force
Majeure. In the event either Party is unable, in whole or in part, to carry out its obligations under this Agreement, those
obligations insofar as they are affected by such an Act of God, shall be suspended during the continuance of any such disability,
and such Party shall not be liable to any other Party hereto if the cause of such disability is remedied insofar as reasonably
possible with reasonable dispatch, except that the settlement of any strike, lockout, or other industrial disturbance shall be
conclusively deemed to be wholly within the discretion of the Party whose obligations are suspended by reason hereof. The term
“Act of God” as employed herein shall mean any event which is not reasonably within the control of the Party affected.
In the event that the failure of either Party hereto to perform any obligation hereunder by reason of an Act of God continues for
more than thirty (30) days, the other Party hereto may terminate this Agreement upon ten (10) business days’ notice following that
thirty (30) day period.

 

10.8         Non-Agency
Relationship. Nothing in this Agreement shall be deemed to constitute a partnership, joint venture or agency relationship between
the parties. Each Party shall be conclusively deemed to be an independent contractor and not under the control or supervision of
any other Party.

 

    	7

    	 

    

 

10.9         Exhibits. The
Exhibits form part of this Agreement and shall have full force and effect as if expressly set out in the body of this Agreement
and reference to this Agreement shall include the attached Exhibits.

 

10.10         Non-Assignment.
Except as expressly provided herein, this Agreement is not assignable except with the prior written consent of the parties.

 

10.11         Non-Transfer
of Rights. Except as expressly provided herein, this Agreement does not transfer any rights in Confidential Information, Intellectual
Property Rights, or constitute an offer to sell or create other obligations.

 

10.12         Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original
and all of which shall constitute the same instrument, but only one of which need be produced.

 

In
Witness Whereof, the Parties have caused their duly authorized representatives to execute this Agreement.

 

	CDX, Inc.	 	Next Dimension Technologies, Inc.
	 	 	 
	By:	      	 	By:	     

 

	Name:	Daniel Yazbeck	 	Name:	William Royea
	 	 	 	 	 
	Title:	President	 	Title:	President
	 	 	 	 	 
	Date:	November 1, 2013	 	Date:	November 1, 2013

 

    	8

    	 

    

 

Exhibit A: Statement of Work

 

Summary

 

	Task description 	 	Pe,formance time	 	Budget
	Task 1.1: Development of a testing platform for off-site, laboratory-based testing of cannabis	 	28 weeks	 	 
	Task 1.2: Development of a sensor array for quantitative detection of THC and CBD	 	18 weeks	 	 
	Task 2.1: Development of a novel sampling sub-system for vapor phase analysis of cannabis vapor	 	18 weeks	 	 

 

Additional tasks shall be added upon mutual writtenagreement.

 

    	9

    	 

    

 

Task 1.1: Development of a
testing platform for off-site, laboratory-based testing of cannabis

 

	Task objective	
        NDT will develop: (1) a      capable
of discriminating between 10 different strains of simulated cannabis, (2) a laboratory-based testing system that can be interfaced
to standard, commercially available measurement instruments and allow testing of the sensor array with samples of cannabis flower,
and (3) software to control and allow collection of raw data from the laboratory-based testing system. At the conclusion of the
task, NDT will deliver the laboratory-based testing system to CDX for further testing and data collection at an off-site laboratory
facility.

	Key deliverables and deadlines	
        ·   
        Development of a sensor array that is capable of detecting 3 strains of cannabis (completed by week 13)

        ·   
        Development of a sensor array that is capable of detecting 10 strains of cannabis (completed by week 28)

        ·   
        Development of a laboratory-based testing system that can be interfaced to standard, commercially available measurement instruments
        and allow for testing of the sensor array with samples of cannabis flower (completed by week 28)

        ·   
        Development of software to control and collect raw data from the laboratory-based testing system (completed by week 28)

        ·   
        Delivery of an oral presentation on the status of the 3-strain sensor array (to be scheduled following week 10)

        ·   
        Delivery of an oral presentation on the status of the 10-strain sensor array and laboratory-based testing system (to be scheduled
        following week 24)

        ·   
        Delivery of the laboratory testing system, associated software, and three (3) sensor arrays to a delivery address to be provided
        by CDX (shipped by week 28).

	Performance time	28 weeks
	Anticipated start date	November 1, 2013
	Anticipated completion date	May 16, 2014
	Total budget	
	Payment schedule	
        ·   $   
        upon completion of week 22 (due within 10 days of invoice)

        ·   
        $    upon shipment oflaboratory-based testing system (due within 10 days of invoice)

	Disclaimer	NDT will use reasonable efforts to achieve the performancegoals specified by CDX. Notwithstanding, the proposed work is developmental in nature, and thus NDT makes no representation and provides no guarantee that the performance goals specified by CDX will be attained.

 

    	10

    	 

    

 

Task 1.2: Development of a sensor array for quantitative
detection of THC and CBD

 

	Task objective	
        NDT
        will develop a        that is capable of        detecting THC
        and CBD in cannabis flower samples. At the conclusion of the task, NDT will deliver samples of the final sensor array to CDX
        for further testing and evaluation.

	Key deliverables and deadlines	
        ·   
        Delivery of an oral presentation on the status of the sensor array development program (to be scheduled following week 6)

        ·   
        Delivery of an oral presentation on the status of the sensor array development program (to be scheduled following week 12)

        ·   
        Delivery of an oral presentation on the status of the sensor array development program (to be scheduled following week 18)

        ·   
        Delivery of five (5) sensor arrays with associated measured performance data to a delivery address to be provided by CDX (shipped
        by week 18).

	Performance time	18 weeks
	Anticipated start date	May 19, 2014
	Anticipated completion date	September 30, 2014
	 	 
	Payment schedule	
        ·   upon
        completion of week 6 (due within 10 days of invoice)

        ·   upon
        completion of week 12 (due within 10 days of invoice)

        ·   upon
        completion of week 18 (due within 10 days of invoice)

	Disclaimer	NDT will use reasonable efforts to achieve performance goals specified by CDX. Notwithstanding, the proposed work is developmental in nature, and thus NDT makes no representation and provides no guarantee that the performance goals specified by CDX will be attained.

 

    	11

    	 

    

 

Task 2.1: Development of a novel
sampling sub-system for vapor phase analysis of cannabis vapor

 

	
         Task objective
	NDT will design a new sampling sub-system for use in an integrated, portable cannabis detector. The system will consist of: (1) a        can be integrated into an electronic readout system, (2) a        (3) a     switch (optional, depending on the overall detector architecture), and (4)           that interfaces to the sensor        and provides electrical connection to the readout electronics. The system will be optimized and tested for cannabis and compounds associated with cannabis. The components for three (3) completed sampling sub-systems will be delivered to CDX for further testing and evaluation.
	Key deliverables and deadlines	
        ·   Delivery
        of an oral presentation on the design and development of the sampling sub-system (to be scheduled following week 6)

        ·   Delivery
        of an oral presentation on the design and development of the sampling sub-system (to be scheduled following week 12)

        ·   Delivery
        of an oral presentation on the design and development of the sampling sub-system (to be scheduled following week 18)

        ·   Delivery
        of three (3) completed sampling sub-systems along with associated measured performance data to a delivery address to be provided
        by CDX (shipped by week 18).

	Performance time	18 weeks
	Anticipated start date	May 19, 2014
	Anticipated completion date	September 30, 2014
	Total budget	 
	Payment schedule	
        ·         upon
        completion of week 6 (due within 10 days of invoice)

        ·         upon
        completion of week 12 (due within 10 days of invoice)

        ·         upon
        completion of week 18 (due within 10 days of invoice)

	Disclaimer	NDT will use reasonable efforts to achieve performance goals specified by CDX. Notwithstanding, the proposed work is developmental in nature, and thus NDT makes no representation and provides no guarantee that the performance goals specified by CDX will be attained.

 

    	12

    	 

    

 

Exhibit
B: Option to exclusive license in the Field

 

1.          NDT
hereby grants to CDX an option to negotiate a royalty-bearing, exclusive license to any Existing Intellectual Property Rights owned
by or licensed to NDT that are required to commercialize products in the Field (the “Option”). During the Option Term,
as defined below, CDX shall have the right to use the NDT’ s Existing Intellectual Property Rights for internal research and evaluation
purposes only. Subject to the rights, if any, of the United States Government pursuant to 35 U.S.C. §200, et seq., as well
as any rights reserved elsewhere by the U.S. Government to use the Existing Intellectual Property Rights, NDT shall not offer a
license under the Existing Intellectual Property Rights in the Field to any third party which is inconsistent with the Option granted
herein.

 

2.          The
term for the exercise of the Option shall commence on the Effective Date of this Agreement and shall continue for a period of twelve
(12) months, unless earlier terminated by the exercise of the Option hereunder or the written notice by CDX to NDT that the Option
is terminated (“Option Term”).

 

3.          In
consideration of the Option granted hereunder, CDX agrees to pay to NDT the sum of          
sand dollars ($) within ten (10) business days of an invoice from NDT to be submitted on or after March 31, 2014. Such amounts
shall be nonrefundable and noncreditable against any future license consideration.

 

4.          CDX
may exercise the Option upon written notice to NDT during the Option Term. Upon NDT’s receipt of such written notice, the parties
agree, within a ninety (90) day period, to negotiate in good faith to attempt to establish the terms of a license agreement granting
CDX exclusive rights to make, have made, use and sell products in the Field under NDT’s Existing Intellectual Property Rights.
Such license agreement shall include at least the following provisions as detailed in Exhibit C: license fee, annual maintenance
payments/minimum royalties, milestone payments (where applicable) and royalty payments, payment of all past and future costs incurred
by NDT associated with the prosecution and maintenance of the Existing Intellectual Property Rights, a commitment by CDX to exert
their best efforts to commercialize licensed products in the Field as soon as practicable, the right of NDT to terminate the license
agreement should CDX not meet specified due diligence milestones or should CDX challenge the validity of the Existing Intellectual
Property Rights, a commitment to maintain the confidentiality of the Patent Rights, and indemnity and insurance provisions satisfactory
to NDT and its insurer. Notwithstanding anything in this Option Agreement to the contrary, the exercise of the Option hereunder
by CDX shall only require the parties to negotiate in good faith to attempt to enter into a license, and shall not require either
party to enter into such a license unless the terms and conditions for such license are satisfactory to each party at its sole
discretion. If such license
agreement has not been executed within ninety (90) days from NDT’ s receipt of CDX’ s written notice to exercise the Option, this
Option Agreement shall be deemed terminated and NDT shall be free to enter into an exclusive or non-exclusive license to the Existing
Intellectual Property Rights in the Field with any other company.

 

    	13

    	 

    

 

Exhibit C: Contemplated terms for Exclusive License Agreement

 

	#	 	Terms	 	Details
	1	 	Parties	 	Licensor: Next Dimension Technologies (NDT) 

Licensee: CDX (CDX)
	 	 	 	 	 
	2	 	Not Legally Binding	 	
        ·  This
        term sheet is not a legally binding contract

        ·  The
        parties have no obligations to each other and should not undertake any relevant obligations unless and until a formal agreement
        is executed

        ·  This
        term sheet states concepts to be reflected in formal contracts, but not the actual wording.

	 	 	 	 	 
	3	 	Technology Description	 	Chemical sensing technology.
	 	 	 	 	 
	4	 	Expected Licensable IP	 	All patent rights licensed to NDT relating to chemical sensing technology in the CDX Field of Use.
	 	 	 	 	 
	5	 	CDX Field of Use	 	The use of sensors and their associated electronics and signal processing technology to characterize cannabis or to detect or to quantify compounds in cannabis for applications in all markets except for law-enforcement.
	 	 	 	 	 
	6	 	Territory	 	Worldwide
	 	 	 	 	 
	7	 	Exclusivity	 	Exclusive rights where NDT has the ability to grant exclusivity. Non-exclusivity where NDT lacks the ability to grant exclusivity.
	 	 	 	 	 
	8	 	Rights Covered	 	Make, use, sell, have made, offer for sale and import.
	 	 	 	 	 
	9	 	Term	 	Last to expire of the currently licensed NDT patents.
	 	 	 	 	 
	10	 	License fees	 	                     up-front license fee due within 30 days of execution of the license agreement
	 	 	 	 	 
	11	 	Royalty	 	
        ·  Royalties
        on gross sales of products that utilize Existing Intellectual Property Rights as follows:

         

        -  % royalty on disposable sensors / sensor
arrays

         

        -  % royalty on devices that utilize sensors
        / sensor         arrays

         

        -  % royalty on accessories for devices that
utilize sensors / sensor arrays

	 	 	 	 	 
	12	 	Minimum royalties	 	
        ·  CDX
shall pay to NDT a minimum royalty of $  K per year, paid in equal quarterly installments.

 

    	14

    	 

    

 

	 	 	 	 	
        ·  The
        minimum royalty due in accordance with this paragraph shall increase to $      per year beginning
        two years after execution of the license agreement, or upon the date of first sale of products using licensed NDT technology, whichever
        occurs sooner.

         

        ·  The
        royalty on product sales shall be creditable towards minimum royalty payments. For partial years, all amounts will be determined
        on a pro-rata basis.

	 	 	 	 	 
	13	 	Milestone payments	 	
        ·  CDX
        shall make a $      milestone payment to NDT upon recognizing $5M in cumulative gross sales of product(s)
        utilizing licensed NDT technology.

         

        ·  CDX
        shall make a $      milestone payment to NDT upon recognizing $1OM in cumulative gross sales of product(
        s) utilizing licensed NDT technology.

         

        ·  CDX
        shall make a $      milestone payment to NDT upon recognizing $25M in cumulative gross sales of product(s)
        utilizing licensed NDT technology.

	 	 	 	 	 
	14	 	Performance milestones	 	
        ·  CDX
        shall invest at least $      per year in research and development towards the commercialization of
        product(s) in the Field until annual gross of product(s) in the Field equals or exceeds $5M.

         

        ·  For
        purposes of this paragraph, R&D investments include moneys expended by CDX both internally and externally (e.g. through joint-development
        efforts funded by CDX)

	 	 	 	 	 
	15	 	IP rigts 

revers10 

n	 	
        Licensed IP rights revert to NDT under the following conditions:

        ·  Non-payment
        of payments due under license agreement

        ·  Non-compliance
        with commercialization due diligence

	 	 	 	 	 
	16	 	IP prosecution and maintenance	 	CDX shall reimburse NDT for ongoing prosecution and maintenance costs and fees incurred by NDT on or after the effective date of the license agreement.

 

    	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]